Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.31
-$0.01-3.13%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 823.97% | 392.10% | -81.30% | -56.41% | 24.37% |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.56% | -76.22% | -92.50% | -54.83% | 19.61% |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 15.57% | 0.00% | 116.00% | -- | -- |
| Total Current Assets | 493.44% | 137.67% | -81.00% | -42.13% | 40.49% |
|
|
|||||
| Total Current Assets | 493.44% | 137.67% | -81.00% | -42.13% | 40.49% |
| Net Property, Plant & Equipment | -30.87% | -28.82% | -22.76% | -20.12% | -17.46% |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -71.54% | -59.25% | -84.91% | -86.15% | -41.71% |
| Total Assets | 103.43% | 41.55% | -64.18% | -36.82% | -10.34% |
|
|
|||||
| Total Accounts Payable | -69.09% | -27.91% | 139.70% | 571.64% | 53.62% |
| Total Accrued Expenses | -68.25% | -45.21% | -25.06% | -38.21% | -5.45% |
| Short-term Debt | -- | -10.40% | -75.88% | -95.26% | -90.66% |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -46.96% | 184.94% | 54.64% | 262.96% | 367.17% |
| Total Finance Division Other Current Liabilities | -- | -- | -50.00% | -99.43% | -99.69% |
| Total Other Current Liabilities | -- | -- | -50.00% | -99.43% | -99.69% |
| Total Current Liabilities | -63.71% | -7.19% | 6.49% | -75.37% | -69.99% |
|
|
|||||
| Total Current Liabilities | -63.71% | -7.19% | 6.49% | -75.37% | -69.99% |
| Long-Term Debt | -82.22% | -70.87% | 21.44% | -- | -- |
| Short-term Debt | -- | -10.40% | -75.88% | -95.26% | -90.66% |
| Capital Leases | -44.06% | -38.83% | -31.46% | -27.76% | -24.75% |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -87.52% | -95.28% | -94.91% | -- | -- |
| Total Liabilities | -64.67% | -33.09% | -16.39% | -67.91% | -59.11% |
|
|
|||||
| Common Stock & APIC | 44.96% | 34.90% | 19.01% | 293.49% | 324.24% |
| Retained Earnings | -18.64% | -22.24% | -28.77% | -26.02% | -39.03% |
| Treasury Stock & Other | -336.36% | 40.43% | -1,750.00% | -58.82% | 191.67% |
| Total Common Equity | 147.63% | 118.63% | -839.95% | 81.55% | 73.55% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 147.63% | 118.63% | -839.95% | 81.55% | 73.55% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 150.09% | 123.90% | -795.61% | 74.71% | 67.97% |
|
|
|||||